Search Here

Nasal sprays are the future of migraine relief, according to researchers developing a new novel prochlorperazine nasal spray formulation that could help treat migraines.

Migraines are characterized by severe pain and headache that can last anywhere from four to seventy-two hours. The condition, which affects around 37 million Americans, can also trigger nausea, vomiting and sensitivity to both light and sound.

Lead researcher Venkata Yellepeddi, Ph.D., and his team from Roseman University of Health Sciences, created a preservative-free device-driven prochlorperazine nasal spray that could lead to the first-in-class spray to treat debilitating migraines.

 ray that could prove useful for compounding pharmacists specifically in the field of pain medicine.

"Prochloperazine is a dopamine receptor antagonist that is widely used as an anti-nausea medication. Comparative clinical studies have shown that prochloperazine provides better pain relief than other anti-migraine drugs such as sumatriptan, metoclopramide, and ketorolac," Yellepeddi said in a news release. "Currently, there are no marketed nasal spray formulations of prochlorperazine available for the treatment of migraine. Prochlorperazine is only available in tablet form, which has delayed onset of action."

The latest research will be presented at the 2014 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in San Diego, Nov. 2-6.